Ghent MSc Sustainable Drug Discovery: Fees and Entry 2027

What is Ghent MSc Sustainable Drug Discovery?

Ghent MSc Sustainable Drug Discovery is a full-time English-taught master’s carrying 120 ECTS over 24 months for the coming international intake. The official 2027 to 2028 catalogue places it in Faculty of Pharmaceutical Sciences and centres the degree on drug discovery, green chemistry, molecular modelling and sustainable development.

The published structure moves through drug-discovery foundations, molecular modelling and omics, mobility specialisation and master’s thesis. Together, those elements define the academic route assessed on this page. One modelled academic year starts with tuition of EUR 7,079.40, about INR 7.51 lakh.

This is one official programme identity rather than a renamed copy of an existing Ghent page. Its distinguishing centre is molecular modelling and omics, and the intended September 2027 route is open to international applicants under the programme’s stated academic and language checks.

A drug-discovery scientist reading of MSc Sustainable Drug Discovery puts molecular modelling and omics beside a real decision made during assessed work. The useful question isn’t whether drug-discovery scientist sounds attractive; it is whether the applicant can show why one approach to molecular modelling and omics was selected, what evidence challenged it and what remained unresolved.

How much does Ghent MSc Sustainable Drug Discovery cost?

The working full-programme total is EUR 50,158.80, about INR 53.23 lakh. It combines the latest Ghent non-EEA tuition information with 24 months at EUR 1,500 from the university’s published living range. It is a planning model, not a frozen 2027 invoice.

Proof of subsistence for immigration is evidence of available money, not an additional charge. Living costs are counted once. Converted at EUR 1 = INR 106.1265, using the ECB daily reference rate checked 22 October 2026.

Ghent’s published planning range is EUR 1,200 to EUR 1,800 per month.Ghent University cost-of-living guidance

Tuition contributes EUR 14,158.80 to this model. The annual basis is EUR 7,079.40; Because this is a consortium or programme-specific route, the live programme fee overrides the standard Ghent planning assumption.

Living contributes EUR 36,000.00 at EUR 1,500 per month, the midpoint of Ghent’s EUR 1,200 to EUR 1,800 range. Housing choice and mandatory mobility can move actual spending materially above or below it.

Flights, visa charges, health cover, translations, a housing deposit, furnishings and currency spread remain outside the table. The total assumes no part-time income, scholarship or fee waiver.

Before committing to MSc Sustainable Drug Discovery, request the exact invoice basis for the 2027 intake and test the household plan against a weaker rupee. A transparent reserve is more useful than treating the estimate as a maximum.

What are the entry requirements for Ghent MSc Sustainable Drug Discovery?

The programme admission page makes the academic test concrete: a relevant life-science, pharmaceutical, chemistry or biomedical degree with laboratory preparation. Ghent also requires a complete verified foreign-degree file and the programme’s B2 English standard. A related degree title cannot replace transcript and syllabus evidence.

Build a table that links each prerequisite to the original course title, credits, mark and syllabus page. For MSc Sustainable Drug Discovery, assessed work in mobility specialisation can strengthen context, but it cannot silently replace a named academic foundation.

The admission risk sits between a relevant life-science, pharmaceutical, chemistry or biomedical degree with laboratory preparation and the intended final work. Resolve any uncertain equivalence before paying for tests, translations or a programme-specific application stage.

Four checks that decide a MSc Sustainable Drug Discovery file

1. A related title is not content evidence

   Credits, marks and official descriptions must expose preparation for drug-discovery foundations and molecular modelling and omics.

2. Verification is part of completeness

   Submitting an upload does not make the degree verified. Delayed verification can leave the application incomplete at the deadline.

3. The programme language rule controls

   The operative requirement is B2. A general B2 page cannot lower a stricter programme or consortium score.

4. Professional recognition remains separate

   MSc Sustainable Drug Discovery is an academic award. Regulated practice, bar admission, clinical registration and employer language rules can require additional steps.

How does an Indian applicant apply for Ghent MSc Sustainable Drug Discovery?

Start with the Ghent application process, but use the exact programme route where it publishes separate selection. This page plans around 1 April 2027. The application must be submitted and academically verified before the controlling deadline; an admission offer does not itself grant a Belgian visa.

Programme match, online application or consortium selection, degree verification, faculty decision, then Belgian student visa

The allowances are preparation estimates, not deadlines or processing times published by Ghent University. Start dates remain unconfirmed.

The academic case should make drug-discovery foundations and molecular modelling and omics easy to verify. A motivation statement explains progression, but it does not create missing credits or replace official records.

Ghent says an application takes about three months on average, so using the final day as a preparation target is unsafe. Verification, translations and test delivery should be complete well before submission.

After an offer, tuition, proof of subsistence, insurance and immigration form a separate chain. The Belgian authority makes the visa decision and can request evidence beyond the university application.

For MSc Sustainable Drug Discovery, programme-specific selection takes priority over the central route. Save the exact 2027 instructions and check for changed dates before the final submission.

What jobs can follow Ghent MSc Sustainable Drug Discovery?

The curriculum supports directions such as drug-discovery scientist, molecular-modelling analyst, pharmaceutical researcher and doctoral applicant. Ghent publishes no audited placement rate or median salary for this exact programme. Belgium’s orientation year gives eligible non-EEA graduates 12 months to seek work, without guaranteeing an offer.

The roles are curriculum-aligned directions, not reported destinations, hiring probabilities, sponsorship claims or salary forecasts.

For drug-discovery scientist, keep one strong output from drug-discovery foundations and state the problem, method, result and limitation. For molecular-modelling analyst, use a different piece of work from molecular modelling and omics rather than relabelling the same assignment.

A route towards pharmaceutical researcher becomes more credible when mobility specialisation feeds directly into master’s thesis. A route towards doctoral applicant may instead require doctoral selection, professional recognition or additional language ability.

Who is Ghent MSc Sustainable Drug Discovery for?

The strongest fit already proves drug-discovery foundations, needs advanced work in mobility specialisation and can fund INR 53.23 lakh without promised employment. A weak fit needs prerequisite repair, professional recognition the degree does not supply or guaranteed placement before enrolment and later job search.

drug-discovery foundations gives MSc Sustainable Drug Discovery a first evidence test for drug-discovery scientist; molecular modelling and omics gives MSc Sustainable Drug Discovery a competing test for molecular-modelling analyst. A decision preserved from drug-discovery foundations, an alternative rejected through molecular modelling and omics and a limitation exposed by mobility specialisation make the drug-discovery scientist claim inspectable rather than aspirational.

mobility specialisation frames the MSc Sustainable Drug Discovery problem that a molecular-modelling analyst would recognise; master’s thesis changes the MSc Sustainable Drug Discovery answer that an doctoral applicant would inspect. The distinction matters because molecular modelling and omics supplies prior method, while drug-discovery foundations records whether that method survived a final assessed test.

An assessed mobility specialisation output supports the MSc Sustainable Drug Discovery route towards pharmaceutical researcher only when its method is visible. Evidence from master’s thesis then challenges the MSc Sustainable Drug Discovery result, evidence from drug-discovery foundations carries it forward, and molecular modelling and omics states what the drug-discovery scientist case still couldn’t establish.

molecular modelling and omics changes MSc Sustainable Drug Discovery from subject interest into capability for doctoral applicant. That MSc Sustainable Drug Discovery capability starts in master’s thesis, meets a counterexample through drug-discovery foundations and ends in mobility specialisation. The same chain may not support molecular-modelling analyst, because its decision context values different evidence.

For MSc Sustainable Drug Discovery, the useful contrast is drug-discovery foundations versus mobility specialisation: the former prepares a drug-discovery scientist question, while the latter tests an molecular-modelling analyst answer. Joining both through molecular modelling and omics gives the MSc Sustainable Drug Discovery portfolio a traceable progression before master’s thesis becomes the final proof point.

A molecular-modelling analyst reading of MSc Sustainable Drug Discovery begins with drug-discovery foundations, but an doctoral applicant reading of MSc Sustainable Drug Discovery begins with mobility specialisation. Putting molecular modelling and omics between those readings reveals whether master’s thesis produced one reusable result or two incompatible claims. That is the choice the final MSc Sustainable Drug Discovery evidence must make explicit.

mobility specialisation gives MSc Sustainable Drug Discovery a first evidence test for pharmaceutical researcher; master’s thesis gives MSc Sustainable Drug Discovery a competing test for doctoral applicant. A decision preserved from mobility specialisation, an alternative rejected through master’s thesis and a limitation exposed by drug-discovery foundations make the pharmaceutical researcher claim inspectable rather than aspirational.

drug-discovery foundations frames the MSc Sustainable Drug Discovery problem that a doctoral applicant would recognise; molecular modelling and omics changes the MSc Sustainable Drug Discovery answer that an molecular-modelling analyst would inspect. The distinction matters because master’s thesis supplies prior method, while mobility specialisation records whether that method survived a final assessed test.

An assessed drug-discovery foundations output supports the MSc Sustainable Drug Discovery route towards drug-discovery scientist only when its method is visible. Evidence from molecular modelling and omics then challenges the MSc Sustainable Drug Discovery result, evidence from mobility specialisation carries it forward, and master’s thesis states what the pharmaceutical researcher case still couldn’t establish.

Master’s thesis changes MSc Sustainable Drug Discovery from subject interest into capability for molecular-modelling analyst. That MSc Sustainable Drug Discovery capability starts in molecular modelling and omics, meets a counterexample through mobility specialisation and ends in drug-discovery foundations. The same chain may not support doctoral applicant, because its decision context values different evidence.

For MSc Sustainable Drug Discovery, the useful contrast is mobility specialisation versus drug-discovery foundations: the former prepares a pharmaceutical researcher question, while the latter tests an doctoral applicant answer. Joining both through master’s thesis gives the MSc Sustainable Drug Discovery portfolio a traceable progression before molecular modelling and omics becomes the final proof point.

A doctoral applicant reading of MSc Sustainable Drug Discovery begins with mobility specialisation, but an molecular-modelling analyst reading of MSc Sustainable Drug Discovery begins with drug-discovery foundations. Putting master’s thesis between those readings reveals whether molecular modelling and omics produced one reusable result or two incompatible claims. That is the choice the final MSc Sustainable Drug Discovery evidence must make explicit.

Within MSc Sustainable Drug Discovery, drug-discovery foundations supplies the opening lens and molecular modelling and omics supplies the specialist pressure. That pairing isn’t interchangeable with mobility specialisation; each tests different evidence. An application centred elsewhere would be a poor match even when the earlier award looks related on a transcript.

The stated prerequisite mix for MSc Sustainable Drug Discovery reaches beyond a degree name: drug-discovery foundations needs transcript evidence, molecular modelling and omics needs content evidence and mobility specialisation benefits from an assessed example. Missing one kind of evidence changes the admission risk in a way motivation can’t repair.

The clearest connection from MSc Sustainable Drug Discovery to drug-discovery scientist runs through drug-discovery foundations, not through the university name. The clearest connection from MSc Sustainable Drug Discovery to molecular-modelling analyst instead runs through molecular modelling and omics. Those connections call for different final-work choices, so one generic career paragraph would hide the decision the student actually faces.

A pharmaceutical researcher case for MSc Sustainable Drug Discovery becomes concrete when mobility specialisation changes a result first framed in drug-discovery foundations. A doctoral applicant case for MSc Sustainable Drug Discovery becomes concrete when master’s thesis exposes an unanswered question from molecular modelling and omics. Neither case turns a curriculum-aligned direction into a promised destination.

MSc Sustainable Drug Discovery has a programme-specific boundary that matters before enrolment. That constraint belongs beside mobility specialisation when the applicant plans electives and beside master’s thesis when the applicant plans final evidence. Ignoring the limit would overstate what this exact degree can change.

At 120 ECTS, MSc Sustainable Drug Discovery gives drug-discovery foundations and molecular modelling and omics finite space rather than unlimited depth. The practical trade-off is whether mobility specialisation deserves that space before master’s thesis. For the drug-discovery scientist route, the answer can differ from the answer for the pharmaceutical researcher route.

The strongest adjacent alternative to MSc Sustainable Drug Discovery would preserve the foundation represented by drug-discovery foundations and molecular modelling and omics but replace mobility specialisation with a capability closer to the intended work. This degree wins only when mobility specialisation and master’s thesis add evidence the alternative cannot produce at similar cost and duration.

A weak portfolio for MSc Sustainable Drug Discovery repeats the degree label without showing a decision. A stronger portfolio links drug-discovery foundations to one decision, molecular modelling and omics to one rejected option and mobility specialisation to one observed consequence. That sequence gives a molecular-modelling analyst reviewer something more credible than programme enthusiasm.

The household case for MSc Sustainable Drug Discovery should be tested against its academic sequence, not only its fee. Funding drug-discovery foundations without reaching master’s thesis leaves the central output unfinished; funding master’s thesis while avoiding molecular modelling and omics misunderstands the route. The full-programme budget therefore belongs beside the full curriculum, not beside year one alone.

The final go or no-go question for MSc Sustainable Drug Discovery is whether progression from molecular modelling and omics to mobility specialisation solves the named capability gap. If the gap is really drug-discovery foundations, prerequisite repair may be better. If the gap is mobility specialisation, this curriculum may fit. Guaranteed drug-discovery scientist employment remains outside any academic structure.

A prepared applicant can use MSc Sustainable Drug Discovery to deepen mobility specialisation instead of repairing drug-discovery foundations. An adjacent applicant needs detailed syllabi and assessed projects that make the overlap explicit.

Financial fit requires room above INR 53.23 lakh for the exclusions. The choice is weaker when the budget depends on a future job, an unconfirmed scholarship or a programme fee being identical to the standard Ghent tariff.

What does the Ghent MSc Sustainable Drug Discovery curriculum cover?

The official 2027 catalogue controls the complete course and option list. These four rows preserve the published programme-level structure without pretending that every option is compulsory or that the plan cannot change before enrolment. The sequence is a planning map for comparison.

• Complete 120 ECTS in the full-time route.
• Follow the compulsory, option and mobility rules of the admitted programme.
• Use the 2027 to 2028 catalogue at enrolment because course availability can change.

The progression from drug-discovery foundations through molecular modelling and omics creates the base for mobility specialisation. That sequence is academically useful when it leads to a bounded question in master’s thesis.

Option choice matters because work for drug-discovery scientist will not use every component in the same way as work for pharmaceutical researcher. The final transcript and portfolio should reveal the chosen direction rather than rely on the programme title alone.

The official catalogue remains the authority for credits, prerequisites, teaching periods and available choices. A high-level structure is not permission to combine incompatible options.

Should an Indian applicant shortlist Ghent MSc Sustainable Drug Discovery?

Shortlist the official MSc Sustainable Drug Discovery route when previous assessed study already supports drug-discovery foundations, the intended work needs mobility specialisation, and the INR 53.23 lakh planning case works without assumed wages or an unawarded scholarship. The curriculum and budget need to support the same choice.

The most defensible value is progression from molecular modelling and omics to master's thesis. That can build evidence for drug-discovery scientist or molecular-modelling analyst, but Ghent publishes no guaranteed placement or salary for this exact programme.

The main limitation is specific. Students move between consortium universities, so the programme cannot be budgeted as two uninterrupted years in Ghent.

Sources

These sources support the programme, admission, cost and immigration information used on this page.

Sources checked on October 22, 2026. Current intake information follows. September 2027 full-time intake.